CANUCK LAW
Reporting That You're Not Getting Elsewhere (Do Your Own Research To Verify)

JULY 9, 2020 BY RONNIE

Plant Based Vaccine Being Developed By GSK & Medicago, And More



medicago
Follow
Medicago
@medicagoinc
Leading clinical-stage biopharmaceutical company using disruptive plant-based and virus-like particle (VLP) technologies to rapidly develop innovative products.
Québec, Canada
medicago.com
Joined October 2017
167 Following
587 Followers
Followed by VIDO-InterVac and L
Tweets
Tweets & replies
Media
Likes
Medicago @medicagoinc · Nov 5, 2019
Under the supervision of the QC Biochemistry Supervisor, the candidate is responsible for the coordination and execution of activities for quality control programs. #BioChem #Medicago #NCJobs #QualityControl #QC #Quality #RTP #GMP #Durham

1. Plant-Based Vaccine In The Works

(Reuters) – The world's largest vaccine-maker GSK has put its vaccine booster technology to work in a potential new COVID-19 shot, to be developed with a ***Canadian***

biopharmaceutical company backed by tobacco company Philip Morris.

Rather than developing its own vaccine in the global race to combat the pandemic, GSK has instead focused on contributing its adjuvant technology to at least seven other global companies, including Sanofi and China's Clover.

There are no approved vaccines for the respiratory illness caused by the new coronavirus, ***but 19 vaccines are being trialed in humans globally*** and some treatments, such as Gilead's remdesivir, have been approved in certain regions.

GSK said on Tuesday the ***companies aimed to make their vaccine available in the first half of next year and produce about 100 million doses by the end of 2021***. An early-stage human trial of three different dosage levels is expected to begin in mid-July.

Medicago, headquartered in Quebec City, Canada, is privately owned. ***PMI has a 33% stake***, and Mitsubishi Tanabe Pharma holds the remainder.

This seems to be for real, a plant-based vaccine to the alleged CV pandemic. However, there are a lot of things to consider, especially who is behind this vaccine. It's also worth looking at the lobbying and influence peddling that goes on.

In its press release, GSK outlined the agreement and pointed out that Medicago is 2/3 owned by Mitsubishi Tanabe Pharma (MTPC), and 1/3 by Philip Morris International (PMI). Apparently Philip Morris — yes the cigarette company — is reconsidering its ownership stake in Medicago.

So GlaxoSmithKline and Medicago are going to develop a plant-based vaccine. Let's take a look into them.

2. Gates Foundation A Regular Donor To GSK



Year	Amount	Purpose
Nov 2011	$16,956,274	HIV research
Nov 2012	$2,098,761	HIV research
Nov 2013	$2,347,273	TB/Malaria
Oct 2014	$1,281,469	Ebola vaccine
Nov 2014	$6,000,000	Adjuvanted vaccines
Nov 2014	$14,060,000	RTS,S, Malaria
Nov 2014	$1,199,441	Malaria/TB/HIV
Jan 2015	$1,291,432	Malaria/TB
Dec 2015	$10,799,189	Shigella vaccine
Oct 2016	$1,511,994	Malaria testing
Apr 2017	$687,790	Pathogen research
Aug 2017	$1,801,900	TB drugs
Nov 2017	$320,265	Malaria control

Nov 2018	$4,992,331	Shigella serotypes

Gates Foundation

Watch on

The Bill & Melinda Gates Foundation has donated millions to GSK, (GlaxoSmithKline), in recent years. Gates seems to be 100% behind the vaxx agenda.

The Gates Foundation Trust, which is a separate entity from the Foundation, holds millions in stocks and bonds of various pharmaceutical companies. Part 21 of this series laid out some of the vast financial ties Bill Gates has to the pharmaceutical industry.

It should also be noted that the Gates Foundation has heavily financed Imperial College London, and Neil Ferguson's bogus computer models. It also owns virus patents, and is heavily involved in ID2020.

3. Gates/GSK Partnered In AbCellera Grant



TEAM
TECHNOLOGY
PARTNERSHIP
NEWS & EVENTS
CONTACT
AbCellera Receives $175.6 million from the Government of Canada to Discover Solutions for COVID-19 and Build a Manufacturing Facility for Antibody Drugs



This a bit of a side track, but worth mentioning briefly. It was covered in Part 14 of the series that the Bill & Melinda Gates Foundation and GlaxoSmithKline, were 2 of the

partners in the May 2020 grant of $175.6 from the Canadian taxpayers to the company AbCellera.

4. Crestview Lobbyists Hired By GSK





At one time GlaxoSmithKline has 2 registered lobbyists from Crestview Strategy: Chad Rogers and Kate Moseley-Williams. However, there are no filed communications reports. A bit strange to recruit but not use them. However, looking at the other GSK records, there are over 200 reports filed from other people going back to 1996.

Why care about Crestview Strategy? Because they are the same firm that GAVI (funded by

Gates), was using to lobby the Trudeau Government over the last few years.

However, Kate Moseley-William did lobby the Ontario Government in 2019 on behalf of GSK. And bit of information: on June 29, 2020, 8 lobbyists from GSK met with ON officials.

5. GSK's Heavy Lobbying In U.S.



According to Open Secrets, GlaxoSmithKline spends a few million every year lobbying in the U.S., and has anywhere from 10 to 60 lobbyists on the payroll. But that probably has no influence on its ability to get FDA approval on its products.

6. Medicago ON VLP/Plant Technology

In very broad strokes, Medicago would be using plants to generate VLP (virus-like particles) which replicate CV and can be given to people to develop immunity. Replicating a previous technique for CV is essentially the partnership that GSK and Medicago would be involved in.

7. Crestview's Jason Clark Now With Medicago

crestview strategy

WHAT WE DO WHO WE ARE NEW

Our Team

MEENA AIER
ASHTON ARSENAULT
MARINA BANISTER
ZAKERY BLAIS
ANDREW BRANDER
JESSICA BROWN
MELISSA CAOUETTE
NATHAN CARR
MORGAN CATES
ALEX CHRESTON
JASON CLARK
CHARLIE CRABB
HAL DANCHILLA

Jason Clark

Jason Clark is a senior consultant with Crestview Strategy working out of the Ottawa Office.

Prior to joining the Crestview Team, Jason has worked in public policy development and advocacy and engagement campaigns, most recently for Engineers Without Borders Canada. Since arriving in Ottawa he has worked work a wide range of Canadian Non-profit organizations on international development and trade issues.

Gavi, the Vaccine Alliance
Consultant: **Jason Clark, Crestview Strategy**
Designated Public Office Holders:
- **Javid Dharas**, Special Advisor | Prime Minister's Office (PMO)

Communication Date: **2019-06-12**

Gavi, the Vaccine Alliance
Consultant: **Jason Clark, Crestview Strategy**
Designated Public Office Holders:
- **Sean Phelan**, Policy Advisor, Opposition Leader's Office | House of Commons
- **Elvanee Veeramalay**, Stakeholder Relations Advisor, Opposition Leader's Office

Communication Date: **2019-06-12**

Office of the Commissioner of Lobbying of Canada | Commissariat au lobbying du Canada

lobbycanada.gc.c

Registry of Lobbyists

Registry Search | Reporting Tools | Statistics | Support

Registry Dashboard → Advanced Registry Search → Advanced Registry Search Results → Registration

Registration - Consultant

Return to Advanced Regis

Medicago Inc. / Medicago Inc. / Jennifer Babcock, Consultant

Registration Information

Client name: **Medicago Inc. / Medicago Inc.**
Lobbyist name: **Jennifer Babcock, Consultant**
Initial registration start date: **2018-09-12**
Registration status: **Inactive**
Registration Number: **932133-362841**

Associated Communicati

Total Number of Communicatio

Monthly communication reports months: **0**

Jason Clark • 3rd+
Consultant at Crestview Strategy
1mo •

Proud to have been an advocate for Gavi, the Vaccine Alliance during the 2015 and 2020 replenishment periods. This critical work will help vaccinate 1.1 billion children against deadly diseases by 2025. This work is only possible thanks to the work of implementing countries, donors, corporate partners, multilateral organizations and philanthropists to strengthen local health systems ensuring that the most vulnerable women and girls will receive access to life-saving vaccines. Thank you to both Minister Karina Gould and Hon. Christian Paradis for your leadership CA

Crestview Strategy
2,435 followers
1mo •

+ Follow

A message from PM Justin Trudeau regarding Gavi, the Vaccine Alliance, in recognition of the important work they are doing to protect the world's most vulnerable people. "Gavi saves lives, and Canada is doing it's part"

An interesting fact: Crestview Strategy lobbyist Jason Clark, previously lobbied both the Prime Minister's Office, and the Office of the Official Opposition. Addressed in Part 4, this was done on behalf of GAVI, whom he proudly represented. Now, Clark is registered as a lobbyist with Medicago.

8. Ex-Crestview Lobbyist Jennifer Babcock


Office of the Commissioner of Lobbying of Canada
Commissariat au lobbying du Canada
lobbycanada.gc.c
Registry of Lobbyists
Registry Search
Reporting Tools
Statistics
Support
Registry Dashboard → Advanced Registry Search → Advanced Registry Search Results → Registration
Registration - Consultant
Return to Advanced Regi
Medicago Inc. / Medicago Inc. / Jennifer Babcock, Consultant
Registration Information
Client name: Medicago Inc. / Medicago Inc.
Lobbyist name: Jennifer Babcock, Consultant
Initial registration start date: 2018-09-12
Registration status: Inactive
Registration Number: 932133-362841
Associated Communicati
Total Number of Communicatic
Monthly communication report
months: 0



Gavi, the Vaccine Alliance
Consultant: **Jennifer Babcock, Crestview Strategy**
Registration: **1 of 2 (2018-09-18 to 2019-01-15)**

Gavi, the Vaccine Alliance
Consultant: **Jennifer Babcock, Crestview Strategy**
Designated Public Office Holders:
- **Marilyn Gladu**, Member of Parliament | House of Commons

Communication Date: **2019-06-11**

Jennifer Babcock has been a registered lobbyist both for GAVI, and for Medicago. Incidently, she has also been a lobbyist for Merck, and for the Alliance for Safe Online Pharmacies.

Lobbyist Details

Subject Matter Details

Grant, Contribution or Other Financial Benefit

- Seeking government partnerships and funding to support research, development, and commercialization of vaccines and other medical countermeasures.

Policies or Program

- Raise awareness with government officials and parliamentarians regarding the importance of biopharmaceutical platforms to strengthen preparedness against future outbreaks of emerging infectious disease.

In fact many lobbyists for the firm Crestview Strategy have had Medicago as a client. Another firm, Magnet Strategy Group, has also worked with Medicago. As the information should make clear, the goal of the lobbying is getting funding from the various Governments.

9. Medicago Co-Owner PMI, Heated Cigs



On Tuesday, the ***FDA authorized Philip Morris's IQOS, an electrically heated tobacco unit***, to be marketed as an MRTP (modified risk tobacco product). IQOS is the ***first and only electronic nicotine product to get authorization from the FDA to be marketed as an MRTP***. The company claims that the product is fundamentally different from other tobacco products and also a better choice for smokers.

The FDA stated that IQOS heats tobacco and doesn't burn it. ***The process significantly reduces the production of harmful chemicals***. Smokers will be less exposed to harmful chemicals by switching completely to IQOS. The FDA concluded that IQOS could benefit tobacco users and non-tobacco smokers based on the current evidence.

Philip Morris International (which owns 1/3 of Medicago) just received FDA approval to sell electronically heated tobacco, which they market as a healthier choice for smokers. Rather than get people off cigarettes, a new model is pitched.

There seems to be some cognitive dissonance here. This group helping to develop a vaccine to save lives is also developing a new form of smoking to help kill people. But business is business I guess.

Interestingly, Philip Morris has suggested selling its 1/3 share of Medicago.

10. WHO Considering Many Vaccines



DRAFT landscape of COVID-19 candidate vaccines – 11 April 2020

3 candidate vaccines in clinical evaluation

Platform	Type of candidate vaccine	Developer	Coronavirus target	Current stage of clinical evaluation/regulatory status- Coronavirus candidate	Same platform for non-Coronavirus candidates
Non-Replicating Viral Vector	Adenovirus Type 5 Vector	CanSino Biological Inc./Beijing Institute of Biotechnology	COVID-19	Phase 2 ChiCTR2000031781 Phase 1 ChiCTR2000030906	Ebola
DNA	DNA plasmid vaccine Electroporation device	Inovio Pharmaceuticals	COVID-19	Phase 1 NCT04336410	Lassa, Nipah HIV Filovirus HPV Cancer indications Zika

who.proposed.vaccine.options

For some context, it must be noted that there are many companies working to develop a vaccine using different approaches. This was from the World Health Organization in April. There aren't any plant based vaccines listed, but perhaps the revised list will change that.

Non-Replicating Viral Vector
Adenovirus Type 5 Vector
CanSino Biological Inc./Beijing Institute of Biotechnology

DNA DNA plasmid vaccine
Electroporation device
Inovio Pharmaceuticals

RNA
LNPencapsulated mRNA
Moderna/NIAID

DNA

DNA with electroporation

Karolinska Institute / Cobra Biologics (OPENCORONA Project)

DNA

DNA plasmid vaccine

Osaka University/ AnGes/ Takara Bio

DNA

DNA

Takis/Applied DNA Sciences/Evvivax

DNA

Plasmid DNA, Needle-Free Delivery

Immunomic Therapeutics, Inc./EpiVax, Inc./PharmaJet, Inc.

On second thought, considering what the World Health Organization is allowing to go forward, maybe a plant based virus isn't as bad as some other options.

11. Saini's M-132 Ensures Canada's Participation

Key Funders

It was outlined in Part 7 and Part 9 of the series how Motion M-132 was introduced in the fall of 2017. Hearings were held with lobbyists in 2018, and the findings were formally adopted in March 2019. This motion ensures Canada will be continuously funding vaccine research for Canada ***and the world***. What convenient timing to clear legislative hurdles.

Of course the murders of Barry and Honey Sherman in late 2017 were convenient as well. We wouldn't want any possible virus cure being readily available. Where's the profit in that?

(1) https://money.usnews.com/investing/news/articles/2020-07-07/gsk-philip-morris-venture-tie-up-for-potential-covid-19-shot

(2) https://us.gsk.com/en-us/media/press-releases/gsk-and-medicago-announce-collaboration-to-develop-a-novel-adjuvanted-covid-19-candidate-vaccine/

(3) https://twitter.com/medicagoinc

(4) https://canucklaw.ca/wp-content/uploads/2020/07/who.proposed.vaccine.options-1.pdf

(5) http://lobbyist.oico.on.ca/

CLICK HERE, for the Federal Lobbying Registry.

(6) https://lobbycanada.gc.ca/app/secure/ocl/lrs/do/vwRg?cno=366144&regId=897841#regStart

(7) https://lobbycanada.gc.ca/app/secure/ocl/lrs/do/vwRg?cno=361856&regId=878369&blnk=1

(8) https://lobbycanada.gc.ca/app/secure/ocl/lrs/do/vwRg?cno=362841&regId=888951

(9) https://lobbycanada.gc.ca/app/secure/ocl/lrs/do/vwRg?

cno=362892&regId=885889&blnk=1

(10) https://lobbycanada.gc.ca/app/secure/ocl/lrs/do/vwRg?cno=363869&regId=886566

(11) https://lobbycanada.gc.ca/app/secure/ocl/lrs/do/vwRg?cno=363846&regId=886416.

(12) https://www.opensecrets.org/federal-lobbying/clients/summary?cycle=2018&id=D000000133

(13) https://www.medicago.com/en/technologies/#production-platform

(14) https://marketrealist.com/2020/07/philip-morris-stock-rises-fda-approves-iqos/

(15) https://www.who.int/news-room/detail/13-04-2020-public-statement-for-collaboration-on-covid-19-vaccine-development

CANADA, DRUGS/ALCOHOL, HEALTH, LOBBYING, US, VACCINES